Back to test list

Breast cancer gene expression

Also known as: Prosigna, PAM50

Test category:

Oncology - Breast cancer

Use of test

Purpose:

Gene expression assays are tests which measure the activity of different genes in a sample of tumour tissue. The pattern of gene activity in breast cancer can provide information about the risk of recurrence and likely response to chemotherapy of a breast cancer. The gene expression assay provided by Sonic Genetics is called Prosigna.

Utility:

The Therapeutic Goods Administration limits the information about this test that we may place in the public domain. We would be pleased to provide doctors with detailed information upon request. Please email us at info@sonicgenetics.com.au. We recommend that patients seek further information from their doctors.

Ethical considerations:

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Methodology:

RNA is extracted from a small section of formalin fixed tumour tissue, and RNA molecules from each of 50 genes are counted.

Requesting the test

Ordering:

This test is usually requested by a surgeon or oncologist. Please use the specific request form (see link below).

Request form:

Download the Prosigna request form.

Sample required:

The sample required is formalin-fixed, paraffin embedded tissue (FFPE).

Special instructions:

There are specific sample requirements; pathologists are requested to contact the laboratory for details.

Turnaround time:

10 business days from receipt at testing laboratory.

Price:

$2,900.

This test requires pre-payment. Please contact Sonic Genetics on 1800 010 447.

Rebate:

This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Sonic Genetics has developed literature for doctors. Please email us at info@sonicgenetics.com.au.

Prosigna and PAM50 publications

 

 

Sonic Genetics has developed literature for patients. Please ask your doctor for this information. Australian regulatory authorities do not allow us to provide this information directly to the public.